CBG vs CBC
- CBG
- Mechanism mapped in vitro, plus one small human trial in our registry Low
- CBC
- Only in-vitro pharmacology, with no controlled human trials No primary evidence
From the evidence status row of the table below.
CBG (cannabigerol) and CBC (cannabichromene) are siblings. Both come from CBGA, both are non-intoxicating, and on a shelf of calm-and-comfort products they can pass for interchangeable. CBG is simply the neutral form of that shared "mother" precursor, while CBC sits on a separate major branch the plant reaches through CBCA. Where they part company is the evidence, and the gap is wide: our registry holds one small human trial for CBG and essentially none for CBC.
How to read this. Verified science appears as fact with a grade beside it: chemical identity, non-intoxicating status, biosynthetic origin and CBG's laboratory (in-vitro) receptor pharmacology. Claims about effects or benefits come from others, so they arrive attributed ("marketed for…," "some users report…") with their limits set beside them. Grade ladder: the six-rung evidence ladder; where evidence is missing, the entry reads "catalogue in progress." Not medical or legal advice.
Side by side
| CBG | CBC | |
|---|---|---|
| Full name | CBGCannabigerol | CBCCannabichromene |
| Formula / CAS | CBGC₂₁H₃₂O₂ · CAS 25654-31-3 · PubChem CID 5315659 | CBCC₂₁H₃₀O₂ · CAS 20675-51-8 |
| Intoxicating? | CBGNo. Non-intoxicating Established | CBCNo. Non-intoxicating Established |
| General legal status (2026, US) | CBGGenerally federally legal when hemp-derived (≤0.3% delta-9 THC), under the 2018 Farm Bill; state rules vary and are still changing; informational, not legal advice | CBCThe same federal hemp rules generally cover hemp-derived CBC; FDA has not approved it as a food or supplement; state rules vary and are still changing; informational, not legal advice |
| Commonly marketed for (attributed) | CBGMarketed for everyday calm, focus, gut comfort and skin. These are third-party claims, not established | CBCMarketed for mood, inflammation, skin and "entourage" support. These are third-party claims, not established, and the evidence is preclinical only |
| Evidence status (graded) | CBGMechanism mapped in vitro, plus one small human trial in our registry Low | CBCOnly in-vitro pharmacology, with no controlled human trials No primary evidence |
The six rungs, and the words each one permits
- grade: Established
- Settled science — replicated human data, or biochemistry that is not in dispute. “is shown to”
- grade: Demonstrated
- Shown reproducibly in controlled experiments — typically laboratory (in-vitro) work. “has been shown to”
- grade: Emerging
- An early signal — preclinical (animal) work, or human evidence too limited to settle the question. “may · early evidence suggests”
- grade: Low
- Limited and low-confidence — sparse, indirect, or single-source data. “limited evidence · unclear”
- grade: Hypothesized
- Proposed and plausible — but not yet shown. “proposed mechanism”
- grade: Not supported
- Tested, and the evidence does NOT support it. This is a finding against the claim — not an absence of evidence. “evidence does not support”
- Catalogue in progress
- Not a rung: our registry holds nothing graded on the question yet. Absence is not evidence against.
A grade rates the support for a claim across the literature, never a single study. How we grade evidence.
- How to read a cell
- An oxblood ring holds the direction: a bar: blocks; a chevron: activates; a chevron with a bar: activates, then desensitises; two bars: damps activation. A gold ring with a dot: recorded in a review, direction qualified by the source, no rung of its own. A dashed frame: no graded interaction in our registry.
- CB1 cannabinoid receptor
- CBG: blocks (antagonist; drawn as a bar), in vitro grade: Demonstrated study type: In vitro Cascio 2010. CBC: no graded interaction in our registry.
- CB2 cannabinoid receptor
- CBG: no graded interaction in our registry. CBC: no graded interaction in our registry.
- α2-adrenoceptor
- CBG: activates (agonist; drawn as a chevron), in vitro grade: Demonstrated study type: In vitro Cascio 2010. CBC: no graded interaction in our registry.
- 5-HT1A serotonin receptor
- CBG: blocks (antagonist; drawn as a bar), in vitro grade: Demonstrated study type: In vitro Cascio 2010. CBC: no graded interaction in our registry.
- TRPV1 and TRPV2 ion channels
- CBG: activates, then desensitises (agonist, then desensitiser; drawn as a chevron with a bar), in vitro grade: Demonstrated study type: In vitro De Petrocellis 2011. CBC: no graded interaction in our registry.
- TRPM8 ion channel
- CBG: blocks (antagonist; drawn as a bar), in vitro grade: Demonstrated study type: In vitro De Petrocellis 2011. CBC: no graded interaction in our registry.
What the evidence settles
Shared ancestry takes the two only so far. Both are non-intoxicating Established and both derive from CBGA, but the pharmacology anyone can cite belongs to CBG. In vitro, Cascio 2010 found it acts as an α2-adrenoceptor agonist, a 5-HT1A antagonist and a CB1 antagonist, and De Petrocellis 2011 showed it modulates TRP channels. The mood and inflammation effects marketed for CBC rest on preclinical work and are not established in humans.
- CBG identity & origin Established: CBG is the neutral, decarboxylated form of CBGA, the plant's shared "mother" precursor.
- CBC identity & origin Established: C₂₁H₃₀O₂, CAS 20675-51-8. The plant builds CBC from CBGA along a separate major branch, by way of its acid form CBCA, and the result is a structural isomer of CBD and THC.
- CBG receptor pharmacology Demonstrated · in vitro: agonist at the α2-adrenoceptor and antagonist at 5-HT1A and CB1 (Cascio 2010); desensitiser at TRPV1/TRPV2 and antagonist at TRPM8 (De Petrocellis 2011). Blood-pressure caution: because CBG acts on α2-adrenoceptors, which help regulate blood pressure, consult a clinician if you take cardiovascular medication.
- CBG preclinical signals Emerging: Borrelli 2013 reported reduced inflammation in a mouse model of colitis, and Appendino 2008 found antibacterial activity in vitro, including against MRSA. Neither result is established in humans.
- CBC human evidence No primary evidence: No controlled human trial has established any effect of CBC. The mood, anti-inflammatory and skin claims on CBC products trace back to preclinical lab and animal studies, so a brand repeating them is citing cell and animal data, whatever the label implies. We report those claims without vouching for them.
- A known gap for CBG No primary evidence: our registry holds no primary study of CBG and intraocular pressure, in either direction, which leaves any claim that CBG lowers eye pressure or treats glaucoma with nothing to rest on. An empty record is a different thing from a finding against.
- Head-to-head [catalogue in progress]: no controlled human trial has compared the two directly, on any outcome.
Common questions
What's the difference between CBG and CBC?
They are two distinct molecules with one parent, and both are non-intoxicating. CBG is the neutral form of CBGA itself, the shared "mother" precursor. CBC comes off a separate major branch the plant builds from CBGA, which makes it a structural isomer of CBD and THC. Their lab pharmacology differs too, and CBG has more human data to its name. Established
Is CBG or CBC better for inflammation or mood?
Neither is established in humans for inflammation or mood. CBG's best card is a mouse colitis model in which it showed anti-inflammatory activity (Borrelli 2013). CBC's mood and anti-inflammatory claims rest on preclinical lab and animal studies alone. With no controlled human trial establishing either, and none head-to-head, any ranking would be guesswork, and the marketing on both sides runs ahead of the evidence. (not medical advice) Catalogue in progress
Do CBG and CBC get you high?
No. Both are non-intoxicating, and neither produces THC's high. CBG goes a step further in laboratory studies, sitting on the CB1 receptor behind cannabis intoxication as a competitive antagonist (Cascio 2010). CBC has no known record of activating CB1, and neither impairs the way THC does. Established
Do CBG and CBC come from the same source?
Yes: both trace back to CBGA, the plant's parent "mother" cannabinoid. From there the paths split. CBG is just CBGA's neutral (decarboxylated) form, while CBC takes a detour, with an enzyme converting CBGA into CBC's acid, CBCA, which turns into CBC when heated. Same origin, different molecules. Established
Will CBG or CBC show up on a drug test?
Neither is what the test hunts for, since standard drug tests screen for THC and its metabolite. The real risk is trace THC (up to 0.3%) in full- or broad-spectrum products of either compound, enough to trigger a positive; isolates carry less of that risk. Read the certificate of analysis, and remember that no product can promise a clean test. Low
Are CBG and CBC legal?
In the US as of 2026, generally yes at the federal level when they are hemp-derived. The 2018 Farm Bill covers hemp-derived CBG and CBC (≤0.3% delta-9 THC), though the FDA has not approved either as a food or supplement, and state rules vary and keep moving. Abroad, novel-food and cannabis rules differ again. Informational, not legal advice; check the rules where you sell or buy. Established
Informational only — not our claims, and not advice. The statements on this page about potential effects, benefits, or uses reflect claims made by third parties (manufacturers, media, traditional use, or preliminary research) and are presented for educational and informational purposes only. CBG Atlas does not make, adopt, endorse, or affirm these claims, and does not represent them as fact. These statements have not been evaluated by the Food and Drug Administration (or any regulator) and are not intended to diagnose, treat, cure, or prevent any disease. Nothing here is medical, legal, or professional advice; cannabinoid effects, safety, and legal status vary by person, product, and jurisdiction and can change over time. Consult a qualified professional before making any health or purchasing decision. Where we can, we show how strong the evidence is and cite the source; where evidence is thin or absent, we say so. Peregrine Biopharma funds the platform and holds no editorial authority.
Report a safety event: if you experienced a possible adverse effect from a cannabinoid product, please report it via the platform's "Report a safety event" path.
Sources, each one verified: Cascio 2010 (PMID 20002104) · De Petrocellis 2011 (PMID 21175579) · Borrelli 2013 (PMID 23415610) · Appendino 2008. Every grade chip links to /evidence.
Before you act on what you have read
Informational only, not medical advice. CBG Atlas is a scientific reference. Nothing here diagnoses, treats, cures or prevents any disease. Every claim on the page carries the grade of the evidence behind it, and the grade sets the words the claim may use. How we grade evidence.
Each grade rates the support for a claim across the literature. It does not rate any single study. An effect in cells may never show up in people. The grades cover the studies checked up to 9 August 2026. This page is for information and is not medical advice.
Cardiovascular note. CBG is a potent α2-adrenoceptor agonist in vitro, and α2 agonism can lower blood pressure. Anyone taking blood-pressure or other cardiovascular medication should consult a clinician before use. This is educational information, not medical advice.
Funding and independence. Peregrine Biopharma funds the platform and holds no editorial authority.
Report a safety event →Keep exploring
The compounds compared
More comparisons